Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.
Human cytomegalovirus (HCMV) establishes persistent lifelong infections and replicates slowly. To withstand robust immunity, HCMV utilizes numerous immune evasion strategies. The HCMV gene cassette encoding US2 to US11 encodes four homologous glycoproteins, US2, US3, US6, and US11, that inhibit the major histocompatibility complex class I (MHC-I) antigen presentation pathway, probably inhibiting recognition by CD8(+) T lymphocytes. US2 also inhibits the MHC-II antigen presentation pathway, causing degradation of human leukocyte antigen (HLA)-DR-alpha and -DM-alpha and preventing recognition by CD4(+) T cells. We investigated the effects of seven of the US2 to US11 glycoproteins on the MHC-II pathway. Each of the glycoproteins was expressed by using replication-defective adenovirus vectors. In addition to US2, US3 inhibited recognition of antigen by CD4(+) T cells by a novel mechanism. US3 bound to class II alpha/beta complexes in the endoplasmic reticulum (ER), reducing their association with Ii. Class II molecules moved normally from the ER to the Golgi apparatus in US3-expressing cells but were not sorted efficiently to the class II loading compartment. As a consequence, formation of peptide-loaded class II complexes was reduced. We concluded that US3 and US2 can collaborate to inhibit class II-mediated presentation of endogenous HCMV antigens to CD4(+) T cells, allowing virus-infected cells to resist recognition by CD4(+) T cells.
D017951:Antigen Presentation / Q000276:immunology*; D001692:Biological Transport; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D003587:Cytomegalovirus / Q000276:immunology*; D019281:Dimerization; D004721:Endoplasmic Reticulum / Q000276:immunology; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology*; D006056:Golgi Apparatus / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics / Q000276:immunology*; D008247:Lysosomes; D008562:Membrane Glycoproteins / Q000235:genetics / Q000276:immunology; D008565:Membrane Proteins; D010455:Peptides / Q000276:immunology; D016601:RNA-Binding Proteins / Q000235:genetics / Q000276:immunology; D013347:Subcellular Fractions; D014407:Tumor Cells, Cultured; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology
D006023:Glycoproteins; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D017874:Immediate-Early Proteins; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D010455:Peptides; D016601:RNA-Binding Proteins; C456062:US10 glycoprotein, Human herpesvirus 5; C074546:US11 protein, herpesvirus; C095111:US3 protein, cytomegalovirus; C456060:US7 glycoprotein, Human herpesvirus 5; C456061:US8 protein, Human herpesvirus 5; C456063:US9 protein, Human herpesvirus 5; D014764:Viral Proteins